The Effect of High Dose Salbutamol on Muscle Performance

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT01415596
First received: August 11, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.


Condition Intervention
Ergogenic Effects of Salbutamol in Healthy Males
Drug: salbutamol
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • Muscle power

Secondary Outcome Measures:
  • Muscle recovery

Enrollment: 20
Study Start Date: August 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Active Comparator: Salbutamol Drug: salbutamol

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males
  • age 18-45
  • training frequency > 10 hrs/wk
  • informed consent

Exclusion Criteria:

  • smoker or former smoker
  • chronic diseases, as well as asthma
  • allergy to the study drugs
  • intake of any form of medicin or inhibited drugs during the study
  • use of beta2-agonist 14 days before the intervention
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01415596

Locations
Denmark
Bispebjerg Hospital
Copenhagen NW, Denmark, DK-2400
Sponsors and Collaborators
Bispebjerg Hospital
University of Copenhagen
  More Information

No publications provided

Responsible Party: Vibeke Backer, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT01415596     History of Changes
Other Study ID Numbers: SALMUS2011
Study First Received: August 11, 2011
Last Updated: August 11, 2011
Health Authority: Denmark: Danish Medicines Agency
Denmark: Good Clinical Practice

Additional relevant MeSH terms:
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014